ArticleScientific reports2025

COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors.

Augustin Boudoussier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.